concept

SPHINGOLIPID

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SPHINGOLIPID: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

504Connections

1Hypotheses

0Analyses

22Outgoing

50Incoming

4Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	SPHINGOLIPID

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Sphingolipid Metabolism in Neurodegeneration

mechanisms · 3241 words

→

Pathway Diagram

graph TD
    SPHINGOLIPID["SPHINGOLIPID"]
    CERS2["CERS2"] -->|"regulates"| SPHINGOLIPID
    REL["REL"] -->|"regulates"| SPHINGOLIPID
    Ms["Ms"] -->|"regulates"| SPHINGOLIPID
    GENES["GENES"] -->|"contributes to"| SPHINGOLIPID
    TNF["TNF"] -->|"contributes to"| SPHINGOLIPID
    P53["P53"] -->|"contributes to"| SPHINGOLIPID
    Lymphoma["Lymphoma"] -->|"contributes to"| SPHINGOLIPID
    Als["Als"] -->|"contributes to"| SPHINGOLIPID
    Tumor["Tumor"] -->|"contributes to"| SPHINGOLIPID

Outgoing (22)

Target	Relation	Type	Str
TREM2	co_discussed	entity	0.50
STING	co_discussed	entity	0.50
SQSTM1	co_discussed	entity	0.50
TNF	co_discussed	entity	0.50
T CELL	co_discussed	entity	0.50
T CELLS	co_discussed	entity	0.50
SYNAPTIC PLASTICITY	co_discussed	entity	0.50
WHITE MATTER	co_discussed	entity	0.50
STROKE	co_discussed	entity	0.50
VEGF	co_discussed	entity	0.50
SPINAL CORD	co_discussed	entity	0.50
ENDOPLASMIC RETICULUM STRESS	inhibits	concept	0.50
STEM CELLS	inhibits	concept	0.50
ENDOPLASMIC RETICULUM	inhibits	concept	0.50
MTOR SIGNALING	activates	concept	0.50
ALZHEIMER'S	associated_with	concept	0.50
SGMS1	regulates	concept	0.50
PARKINSON'S	associated_with	concept	0.50
6-OHDA	associated_with	concept	0.50
Proteins	inhibits	protein	0.50
Pulmonary Fibrosis	activates	disease	0.50
ALZHEIMER'S	regulates	concept	0.50

Incoming (482)

Source	Relation	Type	Str
Als	associated_with	disease	0.80
INFLAMMATION	activates	gene	0.80
APOPTOSIS	activates	gene	0.80
Als	activates	disease	0.80
Inflammation	therapeutic_target	disease	0.80
INFLAMMATION	therapeutic_target	gene	0.80
INFLAMMATION	associated_with	gene	0.70
APOPTOSIS	therapeutic_target	gene	0.70
Als	therapeutic_target	disease	0.70
Inflammation	associated_with	disease	0.70
Inflammation	activates	disease	0.70
IL1B	activates	gene	0.60
Diabetes	associated_with	disease	0.60
AUTOPHAGY	activates	gene	0.60
NLRP3	causes	gene	0.60
CYTOKINES	activates	gene	0.60
NEURODEGENERATIVE DISEASES	contributes_to	gene	0.60
INFLAMMATION	expressed_in	gene	0.60
LYSOSOME	causes	gene	0.60
MITOCHONDRIA	activates	gene	0.60
Neuropathy	associated_with	disease	0.60
GBAP1	regulates	gene	0.60
NEUROTOXICITY	activates	gene	0.60
GBA1	inhibits	gene	0.60
STAT3	associated_with	gene	0.60
AND	associated_with	gene	0.60
MTOR	activates	gene	0.60
MERTK	activates	gene	0.60
AKT	activates	gene	0.60
ST8SIA1	expressed_in	gene	0.60
MAF	activates	gene	0.60
PI3K	expressed_in	gene	0.60
AKT	expressed_in	gene	0.60
CANCER	associated_with	gene	0.60
APOPTOSIS	contributes_to	gene	0.60
OXIDATIVE STRESS	activates	gene	0.60
ERK	activates	gene	0.60
NEUROINFLAMMATION	expressed_in	gene	0.60
PARKINSON'S DISEASE	therapeutic_target	gene	0.60
UGCG	associated_with	gene	0.60
AUTOPHAGY	inhibits	gene	0.60
CYTOKINES	expressed_in	gene	0.60
GBA	regulates	gene	0.60
HK2	therapeutic_target	gene	0.60
MAVS	activates	gene	0.60
ASTROCYTES	activates	gene	0.60
AGING	expressed_in	gene	0.60
NF-ΚB	activates	gene	0.60
COMPLEMENT	expressed_in	gene	0.60
DNA	expressed_in	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Sphingolipid Metabolism Reprogramming	0.663	neurodegeneration	4R-tau strain-specific spreading pattern

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (4)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
CERS2 genetic deletion rescues IL-10 deficiency inflammation	validation	inflammatory bowel disease	0.850	0.00	IL-10/CERS2 double knockout mi	proposed	N/A
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Validation: Membrane-Nucleation in iPSC Neurons	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,730,000
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000

Related Papers (17)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
EMP1 safeguards hematopoietic stem cells by suppressing sphingolipid metabolism [PMID:40624017]	Li L, Lei Y, Li Y, Xie Y, Hui P, Zang X,	Nat Commun	2025	1
IL-10 constrains sphingolipid metabolism to limit inflammation. [PMID:38383790]	York AG, Skadow MH, Oh J, Qu R, Zhou QD,	Nature	2024	1
PAQR4 regulates adipocyte function and systemic metabolic health by mediating ce [PMID:38961186]	Zhu Q, Chen S, Funcke JB, Straub LG, Lin	Nat Metab	2024	1
Sirtuin 1 mediated ceramide metabolism regulates intestinal mechanical barrier f [PMID:41856194]	Ma X, Liu Q, Mai K, Zhang Y	Int J Biol Macromol	2026	0
Metabolic abnormalities and reprogramming in cats with naturally occurring hyper [PMID:39499136]	["Li Q", "Homilius M", "Achilles E", "Ma	ESC heart failure	2025	0
Reduced circulating sphingolipids and CERS2 activity are linked to T2D risk and [PMID:39792658]	Khan SR, Ye WW, Van JAD, Singh I, Rabiee	Science advances	2025	0
Very long-chain fatty acids drive 1-deoxySphingolipid toxicity. [PMID:41298489]	["Majcher A", "Karsai G", "Yusifov E", "	Nature communications	2025	0
A multi-omics approach identifies the key role of disorders of sphingolipid meta [PMID:39638825]	["Qu Y", "Ma D", "Wu T", "Wang H", "Tian	Scientific reports	2024	0
Disruption of adipocyte HIF-1α improves atherosclerosis through the inhibition o [PMID:35847503]	Wang P, Zeng G, Yan Y, Zhang SY, Dong Y,	Acta pharmaceutica Sinica. B	2022	0
Fumonisin B [PMID:35777715]	["Li M", "Liu S", "Tan L", "Luo Y", "Gao	Food and chemical toxicology :	2022	0
Omega-3 polyunsaturated fatty acids reverse the impact of western diets on regul [PMID:35985403]	["Camacho-Mu\u00f1oz D", "Niven J", "Kuc	Biochemical pharmacology	2022	0
Metabolic Reprogramming-A New Era How to Prevent and Treat Graft Versus Host Dis [PMID:33343357]	["Kumari R", "Palaniyandi S", "Hildebran	Frontiers in pharmacology	2020	0
Evolution to the rescue: using comparative genomics to understand long non-codin [PMID:27573374]	["Ulitsky I"]	Nature reviews. Genetics	2016	0
New insights into the organ-specific adverse effects of fumonisin B1: comparison [PMID:25155190]	["Loiseau N", "Polizzi A", "Dupuy A", "T	Archives of toxicology	2015	0
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Cl [PMID:25452455]	["Stoffel E", "Mangu P", "Gruber S", "Ha	Journal of clinical oncology :	2015	0
Ceramide synthase 4 deficiency in mice causes lipid alterations in sebum and res [PMID:24738593]	["Ebel P", "Imgrund S", "Vom Dorp K", "H	The Biochemical journal	2014	0
Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determine [PMID:23209295]	["Zhu Y", "Massen S", "Terenzio M", "Lan	The Journal of biological chem	2013	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning SPHINGOLIPID in their description or question text

No additional research found